AGL (Gene)

Synonyms:AGL, ENTREZ:178, GDE, HGNC:321, MIM:610860, NM_000028, NM_000642, NM_000643, NM_000644, NM_000645, NM_000646, NP_000019, NP_000633, NP_000634, NP_000635, NP_000637, XM_005270557, XM_017000501, XP_005270614, XP_016855990, amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase
Omim:OMIM:610860
Id:ENSG00000162688
Hgnc:HGNC:321
Entrez:178
Description:amylo-alpha-1,6-glucosidase and 4-alpha-glucanotransferase
This gene encodes the glycogen debrancher enzyme which is involved in glycogen degradation. This enzyme has two independent catalytic activities which occur at different sites on the protein: a 4-alpha-glucotransferase activity and a amylo-1,6-glucosidase activity. Mutations in this gene are associated with glycogen storage disease although a wide range of enzymatic and clinical variability occurs which may be due to tissue-specific alternative splicing. Alternatively spliced transcripts encoding different isoforms have been described. [provided by RefSeq, Jul 2008]

Analyze

Data Distillery
CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View AGL's neighborhood in the knowledge graph.

Playbook Workflow Builder
Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with AGL.

Gene Partnership Appyter
CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using AGL.

Gene and Drug Landing Page Aggregator
GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for AGL.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with AGL.

Results found

Linked to

DISPLAY PER PAGE
This repository is under review for potential modification in compliance with Administration directives.